Results 301 to 310 of about 232,874 (323)

Immunoblot fingerprinting Aspergillus fumigatus

Journal of Immunological Methods, 1989
A new technique for typing Aspergillus fumigatus is presented. This is based on immunoblot fingerprinting each isolate against a rabbit hyperimmune antiserum raised against A. fumigatus NCTC 2109. All isolates were typable and reproducibility for the 16 antigenic bands which formed the basis of the system was excellent.
J P, Burnie, R C, Matthews, I, Clark, L J, Milne   +3 more
openaire   +2 more sources

Serological studies on Aspergillus fumigatus

Mycopathologia et Mycologia Applicata, 1961
1) Extract was obtained by repeated cryolysis of acetone-dried mycelia ofAsp. fumigatus killed by formalin. High titer immune serum could be easily obtained by immunizing rabbits with this extract.
M, FUKUI, J, YASUDA
openaire   +2 more sources

Metabolomics ofAspergillus fumigatus

Medical Mycology, 2009
Aspergillus fumigatus is the most important species in Aspergillus causing infective lung diseases. This species has been reported to produce a large number of extrolites, including secondary metabolites, acids, and proteins such as hydrophobins and extracellular enzymes.
Jens C, Frisvad, Christian, Rank, Kristian F, Nielsen, Thomas O, Larsen   +3 more
openaire   +2 more sources

Developmental regulators in Aspergillus fumigatus

Journal of Microbiology, 2016
The filamentous fungus Aspergillus fumigatus is the most prevalent airborne fungal pathogen causing severe and usually fatal invasive aspergillosis in immunocompromised patients. This fungus produces a large number of small hydrophobic asexual spores called conidia as the primary means of reproduction, cell survival, propagation, and infectivity.
Hee-Soo, Park, Jae-Hyuk, Yu
openaire   +2 more sources

Sequencing the Aspergillus fumigatus genome

The Lancet Infectious Diseases, 2002
Aspergillus fumigatus is the most common mould pathogen of human beings and unusually causes both invasive disease in immunocompromised patients and allergic disease in patients with atopic immune systems. 4% of patients dying in modern European teaching hospitals have invasive aspergillosis and it is the leading infectious cause of death in leukaemia ...
Denning, David W., Anderson, Michael J., Turner, Geoffrey, Latgé, Jean Paul, Bennett, Joan W.   +4 more
openaire   +2 more sources

Insertional mutagenesis of Aspergillus fumigatus

Molecular and General Genetics MGG, 1998
We have investigated transformation with heterologous DNA as a method for insertional mutagenesis of Aspergillus fumigatus. Two methods, polyethylene glycol-mediated transformation of protoplasts and electroporation of germinating spores, were used to establish conditions leading to single-copy integration of transforming DNA at different genomic sites.
J S, Brown, A, Aufauvre-Brown, D W, Holden   +2 more
openaire   +2 more sources

Aspergillus fumigatus

1999
Aspergillus fumigatus has become one of the most important fungal human pathogens in industrialized countries. It causes different diseases like allergic bronchopulmonary aspergillosis, aspergilloma, and invasive aspergillosis depending on the underlying disease as well as the immunological status of the host. A.
openaire   +1 more source

Molecular genetics in Aspergillus fumigatus

Current Opinion in Microbiology, 2000
Manipulation of the genome of the human pathogen Aspergillus fumigatus is not well developed. Approaches and data from related model organisms are being used to develop molecular genetic systems in A. fumigatus; for example, the molecular typing of strains during infection.
Brookman, Jayne L., Denning, David W.
openaire   +3 more sources

Aspergillus fumigatus pan-genome analysis identifies genetic variants associated with human infection

Nature Microbiology, 2021
A. E. Barber, Tongta Sae-Ong, Kang Kang, Bastian Seelbinder, Jun Li, G. Walther, G. Panagiotou, O. Kurzai   +7 more
semanticscholar   +1 more source

Itraconazole resistance in Aspergillus fumigatus

Antimicrobial Agents and Chemotherapy, 1997
Invasive aspergillosis is an increasingly frequent opportunistic infection in immunocompromised patients. Only two agents, amphotericin B and itraconazole, are licensed for therapy. Itraconazole acts through inhibition of a P-450 enzyme undertaking sterol 14alpha demethylation.
Denning, David W., Venkateswarlu, K., Oakley, Karen L., Anderson, M. J., Manning, N. J., Stevens, David A., Warnock, David W., Kelly, Steven L.   +7 more
openaire   +4 more sources